Amarin to Report Third Quarter 2012 Financial Results and Host Conference Call on November 8, 2012

BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 1, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc AMRN, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2012 financial results and provide a business overview on Thursday, November 8, 2012, at 4:30 p.m. ET. The conference call will follow the anticipated release of Amarin's third quarter 2012 financial results earlier that day.

To participate in the call, please dial (877) 407-8033 within the United States or (201) 689-8033 from outside the United States. A replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call dial (877) 660-6853 (inside the United States) or (201) 612-7415 (outside the United States). A replay of the call will also be available through the company's website shortly after the call. For both dial-in numbers please use account number 286 and conference ID 402385. The conference call can also be heard live via the investor relations section of the company's website at www.amarincorp.com.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa^TM (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13817